High-dose treatment with haloperidol: The effect of dose reduction

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 252-256

  Volavka, Jan ^a,b   Cooper, Thomas B ^a,b   Czobor, PÁL ^a,b   Lindenmayer, Jean Pierre ^a,b,c   Citrome, Leslie L ^a,b   Mohr, Pavel ^a   Bark, Nigel ^d  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MANHATTAN PSYCHIATRIC CENTER   (United States)

^d Bronx Psychiatric Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MALE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOIDISM; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0034037033     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00020     Document Type: Article

References (15)

1. Volavka J, Cooper TB, Czobor P, Meisner M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1995;52:837-45.
2. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
3. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper T. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989;46:482-3.
4. Krakowski MI, Kunz M, Czobor P, Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry 1993;44:640-4.
5. Troisi A, Pasini A, DeAngelis F, Spalletta G. Paranoid/belligerence and neuroleptic dosage in newly admitted schizophrenic patients. J Clin Psychopharmacol 1997;17:84-7.
6. Van Putten T, Marshall BD, Liberman R, Mintz J, Kuehnel TG, Bowen L, Aravagiri M, Marder SR. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993;29:315-20.
7. Branchey MH, Branchey LB, Richardson MA. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 1981;138:608-12.
8. Caffey EM Jr, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein G. Discontinuation or reduction of chemotherapy in chronic schizophrenics. J Chronic Dis 1964;17:347-58.
9. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989;155:59-65.
10. Honigfeld G, Klett G. The nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65-71.
11. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212[suppl]:11-9.
12. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976.
13. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
14. Fanous A, Lindenmayer J-P. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J Clin Psychopharmacol 1999;19:275-6.
15. Faraone SV, Green AI, Brown W, Yin P, Tsuang MT. Neuroleptic dose reduction in persistently psychotic patients. Hosp Community Psychiatry 1989;40:1193-5.